Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback